VolitionRx Limited Increase Decrease In Operating Lease Liability
VolitionRx Limited (VNRX) reported Increase Decrease In Operating Lease Liability of -$155.96 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- VolitionRx Limited increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$94.69K.
- VolitionRx Limited increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$61.26K.
- VolitionRx Limited increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$78.59K.
- VolitionRx Limited increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$61.24K.
- VolitionRx Limited increase decrease in operating lease liability for fiscal 2025 was -$262.02K.
- VolitionRx Limited increase decrease in operating lease liability for fiscal 2024 was -$257.20K.
- VolitionRx Limited increase decrease in operating lease liability for fiscal 2023 was -$258.85K.
- VolitionRx Limited increase decrease in operating lease liability for fiscal 2022 was -$232.69K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$94.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$155.96K 10-Q · filed 2026-08-13 | -$234.54K derived: sum of 3 quarters · filed 2026-08-13 | -$295.79K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$61.26K 10-Q · filed 2026-05-14 | -$139.85K derived: sum of 2 quarters · filed 2026-05-14 | -$201.09K derived: sum of 3 quarters · filed 2026-05-14 | -$267.22K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$78.59K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$139.83K derived: sum of 2 quarters · filed 2026-03-31 | -$205.96K derived: sum of 3 quarters · filed 2026-08-13 | -$262.02K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$61.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$127.37K derived: sum of 2 quarters · filed 2026-08-13 | -$183.43K 10-Q · filed 2025-11-13 | -$265.88K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$66.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$122.19K 10-Q · filed 2026-08-13 | -$204.63K derived: sum of 3 quarters · filed 2026-08-13 | -$267.19K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$56.06K 10-Q · filed 2026-05-14 | -$138.51K derived: sum of 2 quarters · filed 2026-05-14 | -$201.06K derived: sum of 3 quarters · filed 2026-05-14 | -$254.86K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$82.45K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$145.00K derived: sum of 2 quarters · filed 2026-03-31 | -$198.80K derived: sum of 3 quarters · filed 2026-03-31 | -$257.20K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$62.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$116.36K derived: sum of 2 quarters · filed 2025-11-13 | -$174.76K 10-Q · filed 2025-11-13 | -$242.03K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$53.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$112.20K 10-Q · filed 2025-08-14 | -$179.47K derived: sum of 3 quarters · filed 2025-08-14 | -$245.66K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$58.40K 10-Q · filed 2025-05-15 | -$125.67K derived: sum of 2 quarters · filed 2025-05-15 | -$191.86K derived: sum of 3 quarters · filed 2025-05-15 | -$256.11K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$67.27K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$133.46K derived: sum of 2 quarters · filed 2025-03-31 | -$197.71K derived: sum of 3 quarters · filed 2025-03-31 | -$258.85K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$66.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$130.44K derived: sum of 2 quarters · filed 2024-11-14 | -$191.59K 10-Q · filed 2024-11-14 | -$250.45K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$64.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$125.39K 10-Q · filed 2024-08-14 | -$184.26K derived: sum of 3 quarters · filed 2024-08-14 | -$242.54K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$61.14K 10-Q · filed 2024-05-13 | -$120.01K derived: sum of 2 quarters · filed 2024-05-13 | -$178.29K derived: sum of 3 quarters · filed 2024-05-13 | -$236.83K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$58.87K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$117.15K derived: sum of 2 quarters · filed 2024-03-25 | -$175.69K derived: sum of 3 quarters · filed 2024-03-25 | -$232.69K 10-K · filed 2024-03-25 |
| 2022-09-30 | -$58.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$116.82K derived: sum of 2 quarters · filed 2023-11-14 | -$173.83K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$58.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$115.55K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$57.01K 10-Q · filed 2023-05-10 | |||
| 2021-09-30 | -$49.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$147.92K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$98.79K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |